Acute Myeloid Leukemia Clinical Trials in Philadelphia, Pennsylvania

15 studies are recruiting for acute myeloid leukemia in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   226 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554406 on ClinicalTrials.gov

2. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   349 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

3. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   227 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06317649 on ClinicalTrials.gov

4. Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Locations

   136 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06672146 on ClinicalTrials.gov

5. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

   This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   206 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04293562 on ClinicalTrials.gov

6. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

   Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

   Stage

   Phase 1

   Ages

   0 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   57 in total

   Run by

   Syndax Pharmaceuticals

   See if you can join NCT04065399 on ClinicalTrials.gov

7. Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

   This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound found in fruits and vegetables. Xylitol has been shown to limit …

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   39 in total

   Run by

   Children's Oncology Group

   See if you can join NCT07022678 on ClinicalTrials.gov

8. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

9. Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

   A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or…

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   90 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT05183035 on ClinicalTrials.gov

10. Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

    A treatment cycle is 28 days. Tagraxofusp will be administered at 9 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 3 consecutive days (or 3 doses over a period not to exceed 10 days if postponement is required to allow for toxicity resolution), followed by azacitidine administered at 75 mg…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania

    Locations

    7 in total

    Run by

    Joshua Zeidner

    See if you can join NCT05442216 on ClinicalTrials.gov

11. CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

    The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconst…

    Stage

    Not phased

    Ages

    Up to 25

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Run by

    Children's Hospital of Philadelphia

    See if you can join NCT03810196 on ClinicalTrials.gov

12. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Penn Medicine - Abramson Cancer Center Perelman, Philadelphia, Pennsylvania

    Locations

    39 in total

    Run by

    CellCentric Ltd.

    See if you can join NCT04068597 on ClinicalTrials.gov

13. Massage Impact on Sleep in Pediatric Oncology

    This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).

    Stage

    Not phased

    Ages

    12 to 21

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Locations

    2 in total

    Run by

    Children's Hospital of Philadelphia

    See if you can join NCT06892158 on ClinicalTrials.gov

14. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in pat…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    44 in total

    Run by

    Kura Oncology, Inc.

    See if you can join NCT05735184 on ClinicalTrials.gov

15. Home Blood Transfusions

    This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Parti…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT07121140 on ClinicalTrials.gov